Side-by-side · Research reference
AOD-9604vsHCG
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED10/47 cited
BFDA-ApprovedHUMAN-REVIEWED12/52 cited
AOD-9604
HGH 176-191 · β3-AR Lipolytic
SQ · Abdomen · Daily fasted
HCG
Glycoprotein Hormone · LH Mimetic
IM or SQ · 2–3×/week
01Mechanism of Action
Parameter
AOD-9604
HCG
Primary target
β3-adrenergic receptor (proposed)Ng 2000
LH receptors on testicular Leydig cellsSchröder-Lange 2025
Pathway
β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2000
hCG → Leydig cell LH receptor → Intracellular cAMP → Steroidogenesis pathway activation → Testosterone synthesis
Downstream effect
Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001
Elevated intratesticular testosterone, restored spermatogenesis, virilization, secondary sex characteristic developmentKonsam 2026Zachariou 2026
Feedback intact?
No GH-axis or IGF-1 feedback
No — exogenous hCG bypasses hypothalamic-pituitary axis; endogenous LH remains suppressed
Origin
Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2000
Heterodimeric glycoprotein (alpha subunit shared with LH/FSH/TSH; beta subunit confers specificity). Available as urinary-derived or recombinant formulations.
Antibody development
—
Rare with recombinant; possible with urinary-derived formulations
02Dosage Protocols
Parameter
AOD-9604
HCG
Frequency
Once daily, fasted
—
Lower / starter dose
150 mcg / day
—
Evidence basis
Phase 2 trials + animal-strongHeffernan 2001Ng 2000
RCT / Meta-analysis / FDA-approvedKonsam 2026Huijben 2026
Duration
8–12 weeks per cycle
—
Reconstitution
Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL
—
Timing
Morning fasted preferred (pre-cardio)
Aligns with circadian lipolysis.
—
Half-life
~30 min plasma
—
Hypogonadotropic hypogonadism (monotherapy)
—
2,000 IU IM/SQ 2–3×/weekKonsam 2026Zachariou 2026
Titrate to normalize testosterone (300–1,000 ng/dL) or achieve target AMH ~7.4 ng/mL.
Combined therapy (hCG + FSH)
—
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wkKonsam 2026Nariyoshi 2025
Preferred for azoospermia; FSH added after initial hCG phase or from outset.
Triple therapy (experimental)
—
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wk + testosterone 100 mg IM q2wkKonsam 2026
May accelerate virilization; reduces hCG requirements (~30% lower cumulative dose vs monotherapy).
Cryptorchidism (pediatric)
—
500–4,000 IU IM 2–3×/week for 3–6 weeks
Duration to sperm appearance
—
12–24 months (median ~18 mo)Huijben 2026Zachariou 2026
Congenital HH may require longer treatment; acquired HH responds faster.
Monitoring
—
Serum testosterone, semen analysis q3–6mo, testicular ultrasound
Thickened seminiferous tubules (>300 μm) on ultrasound predict imminent sperm appearance.Nariyoshi 2025
04Side Effects & Safety
Parameter
AOD-9604
HCG
Injection site reaction
Mild erythema
Pain, erythema (mild, transient)
GI symptoms
Rare mild nausea
—
Cardiovascular
Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)
—
Cancer risk
No GH/IGF-1 axis activity → lower theoretical risk vs HGH
—
Pregnancy / OB
Avoid
—
Gynecomastia
—
Aromatization of elevated testosterone to estradiol; dose-dependent
Testicular discomfort / Edema
—
Rapid testicular growth in hypogonadal males; usually self-limiting
Polycythemia
—
Elevated hematocrit from supraphysiological testosterone; monitor CBC
Mood / Libido changes
—
Variable; usually positive with normalization of testosterone
Acne / Oily skin
—
Androgen-mediated; dose-dependent
Prostate concerns
—
Monitor PSA in older males; hCG restores physiological testosterone (not supraphysiological)
Antibody formation
—
Rare with recombinant; possible with urinary-derived
Absolute Contraindications
AOD-9604
- ·Pregnancy / breastfeeding
- ·Severe cardiovascular disease (caution with β-receptor agonists)
HCG
- ·Androgen-dependent malignancy (prostate, breast cancer)
- ·Hypersensitivity to hCG or excipients
- ·Precocious puberty
Relative Contraindications
AOD-9604
- ·Concurrent β-blocker therapy (theoretical antagonism)
- ·Pheochromocytoma
HCG
- ·Untreated obstructive sleep apnea
- ·Severe cardiovascular disease (polycythemia risk)
- ·History of thromboembolism
05Administration Protocol
Parameter
AOD-9604
HCG
1. Reconstitution
Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.
Add sterile water or bacteriostatic water per manufacturer instructions. Typically 1–2 mL per 5,000–10,000 IU vial. Roll gently — do not shake. Solution should be clear.
2. Injection site
SQ — abdomen preferred. Rotate sites.
Intramuscular: ventrogluteal, vastus lateralis, or deltoid. Subcutaneous: abdomen, avoiding navel (2-inch radius). Rotate sites to prevent lipohypertrophy.
3. Timing
Morning, fasted, ideally pre-cardio for amplified fat oxidation.
Administer 2–3 times per week. Consistent weekly schedule recommended (e.g., Monday/Thursday or Monday/Wednesday/Friday).
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
Lyophilized: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C. Bacteriostatic water extends shelf life to ~30 days; sterile water use within 72 hours.
5. Needle
29–31G, 4–8 mm insulin syringe.
IM: 21–23G, 1–1.5 inch. SQ: 25–27G, 5/8 inch. Inject slowly (30–60 seconds for IM).
06Stack Synergy
AOD-9604
+ MOTS-c
ModerateAOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.
- AOD-9604
- 250–300 mcg SQ · morning fasted (daily)
- MOTS-c
- 5 mg SQ · 2–3× per week (pre-workout)
- Primary benefit
- Fat mobilisation + mitochondrial oxidation, no IGF-1 concern
HCG
— no documented stacks